Page 5 - Zydus Cadila

Zydus gets DCGI nod for conducting phase-3 clinical trials of ZyCoV-D

Company to initiate trials with around 30,000 volunteers

What sets Zydus Cadila apart among indigenous players in Covid vaccine race

The company says the stability of the vaccine is one of its biggest advantages amid dry runs of mass vaccination programmes being conducted in some states

Zydus Cadila receives drug regulator's nod for NAFLD medicine in India

ZydusCadila said it has received approval from the Drug Controller General of India (DCGI) for Saroglitazar Mg, used for the treatment of non-alcoholic fatty liver disease (NAFLD), in the country

Zydus gets DCGI approval for phase-3 clinical trials of Covid-19 therapy

Trials will involve use of Cadila's biological therapy Pegylated Interferon alpha-2b in India

Zydus Cadila gets nod to start phase 3 trials of Covid vaccine on patients

Zydus Cadila said it has received the approval from the Drugs Controller General of India to start phase 3 clinical trials with its biological therapy PegiHep in Covid-19 patients

PM visit will motivate us to 'bridge unmet healthcare needs': Zydus Cadila

Modi visited Zydus Cadila's manufacturing facility near Ahmedabad to take stock of the development of a Covid-19 vaccine.

Modi reviews vaccine development at Zydus Cadila facility near Ahmedabad

Modi spent over an hour at the plant, before leaving for Hyderabad

Pfizer vaccine's -70 degree storage norm tough for most nations: V K Paul

Limited number of doses would not be enough to meet India's demand, adds Niti Aayog member

Zydus completes phase 2 clinical trial in Covid patients with bio-therapy

Zydus Cadila said it has successfully completed a phase 2 clinical trial In Covid-19 patients with its biological therapy, 'PegiHep', and it will now begin phase 3 clinical trial.

Zydus Cadila files investigational new drug application for coronavirus

Drug firm Zydus Cadila said it has filed the investigational new drug application for ZYIL1, positioned for management of critically ill Covid-19 patients

Zydus Cadila Q2 net up four-fold on surge in US sales, strong show at home

Firm prunes net debt by 40% since March 2020; consolidated income up 13%

Zydus Cadila gets USFDA nod for overactive bladder treatment drug

Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Solifenacin Succinate tablets, used for treatment of overactive bladder

Zydus Cadila gets USFDA nod to market Verapamil Hydrochloride Injection

Drug firm Zydus Cadila said it has received final approval from the US health regulator to market Fingolimod capsules and Verapamil Hydrochloride Injection.

Indian samples of global Covid-19 vaccines need to be larger: Experts

Indian players like Bharat Biotech and Zydus Cadila ready for large-scale phase-3 trials

Govt exploring options on financing Covid vaccine development: Health secy

Union Health Minister Harsh Vardhan had on October 4 said that the Centre estimates to receive and utilise 40-50 crore doses of Covid-19 vaccine covering 20-25 crore people by July next year

Zydus Cadila gets USFDA nod for multiple sclerosis treatment drug

Zydus Cadila said it received approval from the USFDA to market Dimethyl Fumarate delayed release capsules, indicated for the treatment of patients with relapsing forms of multiple sclerosis

Zydus Cadila gets tentative USFDA approval to market anti-cancer drug

Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules

Zydus Cadila gets USFDA nod to market mineral supplement tablets

Zydus Cadila said it has received approval from USFDA to market potassium chloride extended release tablets, a mineral supplement used to treat or prevent low amounts of potassium in the blood

India's Covid-19 tally nears 5 mn with one-fifth of total cases active

India took six months to reach the first million covid cases and it has gone from four to 4.9 million in 11 days

Zydus Cadila gets USFDA nod to market its cancer treatment injection

Drug firm Zydus Cadila said it has received final nod from USFDA to market its generic Doxorubicin Hydrochloride Liposome injection, used for treatment of certain types of cancer, in the US